Eli Lilly and Company (NYSE:LLY) Shares Purchased by Wealthspire Advisors LLC

Wealthspire Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 23.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,709 shares of the company’s stock after purchasing an additional 1,672 shares during the quarter. Wealthspire Advisors LLC’s holdings in Eli Lilly and Company were worth $6,724,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Cohen Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 8.7% in the fourth quarter. Cohen Capital Management Inc. now owns 338 shares of the company’s stock valued at $261,000 after acquiring an additional 27 shares in the last quarter. Marshall Investment Management LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $2,516,000. LWM Advisory Services LLC boosted its holdings in shares of Eli Lilly and Company by 2.4% in the fourth quarter. LWM Advisory Services LLC now owns 1,844 shares of the company’s stock valued at $1,424,000 after acquiring an additional 43 shares in the last quarter. TCW Group Inc. boosted its holdings in Eli Lilly and Company by 8.7% during the fourth quarter. TCW Group Inc. now owns 12,589 shares of the company’s stock worth $9,719,000 after buying an additional 1,011 shares in the last quarter. Finally, FPC Investment Advisory Inc. boosted its holdings in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after buying an additional 43 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $874.12 on Monday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm has a market capitalization of $828.82 billion, a PE ratio of 74.65, a PEG ratio of 1.40 and a beta of 0.42. The firm’s fifty day simple moving average is $801.33 and its 200 day simple moving average is $847.66. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has approved a share repurchase program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio is 51.24%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on LLY. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Barclays reduced their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Wells Fargo & Company reduced their price target on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Finally, Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research report on Friday, January 17th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,000.28.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.